Author

G. Grodeland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Ianevski· 2 shared D. E. Kainov· 2 shared E. Zusinaite· 2 shared H. Lysvand· 2 shared M. Bjoras· 2 shared N. Legrand· 2 shared P. Aukrust· 2 shared T. Tenson· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Ianevski

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants

T. T. Tran, E. B. Vaage, A. Mehta, A. Chopra, A. Kolderup, A. K. Anthi, M. Konig, G. Nygard, A. Lind, F. Muller, L. S. H. Nissen-Meyer, P. Magnus, L.-I. S. Trogstad, S. Mjaaland, A. Soraas, , F. Lund-Johansen

This study shows that anti-RBDwt titers correlate with neutralizing antibody levels against multiple SARS-CoV-2 variants and proposes a method to improve immunomonitoring precision and throughput.

bioRxiv · Mar 26, 2022 · PreprintImmunology

Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo

A. Ianevski, R. Yo, H. Lysvand, G. Grodeland, N. Legrand, V. Oksenych, E. Zusinaite, T. Tenson, M. Bjoras, D. E. Kainov

This study combines nafamostat and interferon-alpha to suppress SARS-CoV-2 infection by targeting TMPRSS2 in vitro and in vivo.

bioRxiv · Jun 16, 2021Microbiology

Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo

A. Ianevski, R. Yao, E. Zusinaite, L. S. Lello, S. Wang, E. Jo, J. Yang, E. Ravlo, W. Wang, H. Lysvand, K. Loseth, V. Oksenych, T. Tenson, M. P. Windisch, M. Poranen, , D. E. Kainov

This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology